What question did this study set out to answer?

This study aims to compare overall survival and progression-free survival between FOLFIRINOX and gemcitabine plus nab-paclitaxel in advanced pancreatic adenocarcinoma.

June 20, 2026Therapeutic Advances in Medical OncologyOpen Access

Real-world outcomes of FOLFIRINOX versus gemcitabine plus nab-paclitaxel and prognostic factors in advanced pancreatic cancer: a retrospective cohort study

View Full Paper

Ask AI

Bookmark

This study aims to compare overall survival and progression-free survival between FOLFIRINOX and gemcitabine plus nab-paclitaxel in advanced pancreatic adenocarcinoma.
Retrospective cohort study involving 200 patients with locally advanced or metastatic pancreatic cancer.
Patients received first-line treatment with either FOLFIRINOX or gemcitabine plus nab-paclitaxel.
Overall survival and progression-free survival analyzed using Kaplan–Meier method and Cox proportional hazard models.
Median overall survival was 10.6 months for FOLFIRINOX and 9.6 months for gemcitabine plus nab-paclitaxel (HR 1.05, 95% CI 0.74–1.50; p = 0.78).
Median progression-free survival was 5.19 months for FOLFIRINOX and 4.63 months for gemcitabine plus nab-paclitaxel (HR 1.09, 95% CI 0.77–1.54; p = 0.64).
Objective response rate was 44.2% for FOLFIRINOX compared to 29.1% for gemcitabine plus nab-paclitaxel (p = 0.063).

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Retrospective cohort study compares overall survival and progression-free survival in advanced pancreatic cancer, indicating similar outcomes for both treatments.

Cite This Study

Escriva-Aranda et al. (2026) studied this question.

synapsesocial.com/papers/6a363172db0793dc1a53854e https://doi.org/10.1177/17588359261456797

View Full Paper

Ask AI

Bookmark

Implication

Retrospective cohort study compares overall survival and progression-free survival in advanced pancreatic cancer, indicating similar outcomes for both treatments.

Real-world outcomes of FOLFIRINOX versus gemcitabine plus nab-paclitaxel and prognostic factors in advanced pancreatic cancer: a retrospective cohort study

Key Points

Discussion

Implication

Cite This Study

Real-world outcomes of FOLFIRINOX versus gemcitabine plus nab-paclitaxel and prognostic factors in advanced pancreatic cancer: a retrospective cohort study

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider